McNicoll, Lewis & Vlak Reiterates Ligand Pharmaceuticals Buy, $30 Price Target

McNicoll, Lewis & Vlak reiterated its Ligand Pharmaceuticals LGND Buy rating and $30 price target in a research report published today. In the report, McNicoll, Lewis & Vlak states, "With 8 marketed drugs and more than 50 fully funded programs, we view LGND as a more de-risked biopharmaceutical investment model with an unprecedented number of individual shots on goal." Shares of Ligand Pharmaceuticals were trading at $13.32 at the time of posting, up 0.99% from Friday's market close.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorReiterationAnalyst RatingsLewis & VlakMcNicoll
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!